On February 10, 2026, Medpace shares fell approximately 10% by mid-day and closed down 15.9%, according to data from Quiver Quantitative and GuruFocus. Approximately $10.2 million in trading volume was recorded during the sell-off, reflecting heightened activity well above normal daily averages. The decline occurred despite the company reporting Q4 revenue of $708.5 million and GAAP EPS of $4.67, both of which exceeded Wall Street consensus estimates. Medpace underperformed the broader Nasdaq-100 and the CRO sector, which were flat to modestly positive on the same trading day.
Analyst and financial media commentary was nearly unanimous in identifying the cause. Investor's Business Daily called the bookings shortfall the "key negative" that overwhelmed the sales and profit beat. Seeking Alpha reported the stock dropped over 15% because the book-to-bill ratio missed expectations. GuruFocus noted a "sharp decline” in stock price raising investor concerns about forward demand. Finviz published an analysis focused on cancellations and metabolic-trial mix pressure on margins.
Institutional activity around the earnings date added further context. Principal Financial Group reduced its Medpace stake by 8.4% in a filing disclosed on February 8, 2026, just one day before the earnings release. Meanwhile, Representative David Taylor (R-OH) purchased shares on February 2, 2026, according to MarketBeat. The timing of these transactions relative to the earnings disclosure is relevant to the investigation.
During the Q4 earnings call, several sell-side analysts pressed management on the nature of the booking deterioration. Christine Rains of William Blair asked about direct-fee growth embedded in guidance. Justin Bowers of Deutsche Bank sought to quantify RFP activity and characterize cancellations by therapeutic area and customer. Ann Hynes of Mizuho asked whether the cancellation level was historically unprecedented, to which management responded that, comparing to the prior year, "it was the highest level of cancellations out of backlog." David Windley of Jefferies questioned whether metabolic concentration could drive further cancellations. Charles Rhyee of TD Cowen asked whether cancellations were driven by funding constraints or trial failure. CEO Troendle’s responses described cancellations as "broad-based" and involving "no single large project,” leaving investors without any clear answers.
To receive more information, please fill out the form.
